2026-05-21T23:45:19Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/89952025-04-24T12:39:24Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16968

00925njm 22002777a 4500 dc Rondy, Marc author Larrauri, Amparo author Casado, Itziar author Alfonsi, Valeria author Pitigoi, Daniela author Launay, Odile author Syrjänen, Ritva K author Gefenaite, Giedre author Machado, Ausenda author Vučina, Vesna Višekruna author Horváth, Judit Krisztina author Paradowska-Stankiewicz, Iwona author Marbus, Sierk D author Gherasim, Alin Manuel author Díaz-González, Jorge Alberto author Rizzo, Caterina author Ivanciuc, Alina E author Galtier, Florence author Ikonen, Niina author Mickiene, Aukse author Gomez, Verónica author Kurečić Filipović, Sanja author Ferenczi, Annamária author Korczyńska, Monika Roberta author van Gageldonk-Lafeber, Rianne author I-MOVE+ hospital working group author Valenciano, Marta author 2017 We conducted a multicentre test-negative case-control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42% (95% confidence interval (CI): 22 to 57). It was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus, cancer, lung and heart disease, respectively. Adjusted IVE against influenza B was 52% (95% CI: 24 to 70). It was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: -23 to 67) in patients with diabetes mellitus, lung and heart disease, respectively. 2015/16 IVE estimates against hospitalised influenza in elderly people was moderate against influenza A(H1N1)pdm09 and B, including among those with diabetes mellitus, cancer, lung or heart diseases. Euro Surveill. 2017 Jul 27;22(30). pii: 30580. 10.2807/1560-7917.ES.2017.22.30.30580 1560-7917 1025-496X Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 28797322 http://hdl.handle.net/20.500.12105/8995 case control elderly hospitalisation influenza severe acute respiratory infection vaccine effectiveness vaccine-preventable diseases 2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project